Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys.
apheresis
focal segmental glomerulosclerosis
minimal change nephrotic syndrome
nephrotic syndrome
Journal
Kidney international reports
ISSN: 2468-0249
Titre abrégé: Kidney Int Rep
Pays: United States
ID NLM: 101684752
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
02
04
2021
revised:
22
04
2021
accepted:
26
04
2021
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Apheresis is the gold standard for idiopathic nephrotic syndrome (INS) relapse after transplantation, but it remains unknown whether such treatment is useful for adults with refractory INS on native kidneys. This retrospective study included patients older than 16 years with biopsy-proven refractory (persistent nephrotic syndrome on corticosteroids plus at least 1 immunosuppressive drug) INS treated by apheresis and followed for at least 3 months. Between September 1997 and January 2020, 21 patients (focal segmental glomerulosclerosis: 12, minimal change nephrotic syndrome: 9, men: 67%, median age: 34 years) were identified. At last follow-up (12 months), 7 of 21 patients were in complete or partial remission. Remission was associated with older age (51 vs. 30 years, Apheresis may result in remission in adult patients with refractory INS, particularly in those at risk of renal failure, with limited sensitivity to medical treatments, if apheresis is initiated within a year of diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Apheresis is the gold standard for idiopathic nephrotic syndrome (INS) relapse after transplantation, but it remains unknown whether such treatment is useful for adults with refractory INS on native kidneys.
METHODS
METHODS
This retrospective study included patients older than 16 years with biopsy-proven refractory (persistent nephrotic syndrome on corticosteroids plus at least 1 immunosuppressive drug) INS treated by apheresis and followed for at least 3 months.
RESULTS
RESULTS
Between September 1997 and January 2020, 21 patients (focal segmental glomerulosclerosis: 12, minimal change nephrotic syndrome: 9, men: 67%, median age: 34 years) were identified. At last follow-up (12 months), 7 of 21 patients were in complete or partial remission. Remission was associated with older age (51 vs. 30 years,
CONCLUSION
CONCLUSIONS
Apheresis may result in remission in adult patients with refractory INS, particularly in those at risk of renal failure, with limited sensitivity to medical treatments, if apheresis is initiated within a year of diagnosis.
Identifiants
pubmed: 34386662
doi: 10.1016/j.ekir.2021.04.029
pii: S2468-0249(21)01142-6
pmc: PMC8343786
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2134-2143Informations de copyright
© 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.
Références
J Am Soc Nephrol. 2004 Aug;15(8):2169-77
pubmed: 15284302
Kidney Int. 2018 Dec;94(6):1217-1226
pubmed: 30385039
Clin Exp Nephrol. 2014 Apr;18(2):286-90
pubmed: 24535024
Nephrol Dial Transplant. 2015 Mar;30(3):375-84
pubmed: 24589721
Am J Kidney Dis. 2000 Jun;35(6):1166-74
pubmed: 10845832
Am J Kidney Dis. 2004 Feb;43(2):368-82
pubmed: 14750104
Acta Paediatr. 2019 Apr;108(4):757-762
pubmed: 30230027
BMJ. 2019 May 23;365:l1800
pubmed: 31335316
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):2006-13
pubmed: 24903390
BMC Nephrol. 2016 Jul 29;17(1):104
pubmed: 27473582
Int J Nephrol Renovasc Dis. 2020 Jun 18;13:157-162
pubmed: 32606890
Nephron Extra. 2015 Aug 29;5(2):58-66
pubmed: 26557843
J Autoimmun. 2018 May;89:149-161
pubmed: 29307588
J Clin Med. 2019 Mar 02;8(3):
pubmed: 30832362
Clin J Am Soc Nephrol. 2007 May;2(3):445-53
pubmed: 17699450
Kidney Int. 2019 Feb;95(2):281-295
pubmed: 30665569
Pediatr Nephrol. 2018 Apr;33(4):573-584
pubmed: 28451893
Nephrol Dial Transplant. 1998 Aug;13(8):2013-6
pubmed: 9719156
Ther Apher. 1997 Nov;1(4):370-1
pubmed: 10225734
N Engl J Med. 2011 Dec 22;365(25):2398-411
pubmed: 22187987
Sci Transl Med. 2014 Oct 1;6(256):256ra136
pubmed: 25273097
Am J Kidney Dis. 1998 Aug;32(2):230-7
pubmed: 9708606
Nephron. 1996;72(2):318-20
pubmed: 8684548
Kidney Int. 2019 Feb;95(2):268-280
pubmed: 30665568
Nephrol Dial Transplant. 2014 Dec;29(12):2207-16
pubmed: 25416821
N Engl J Med. 1996 Apr 4;334(14):878-83
pubmed: 8596570
Transplantation. 2002 Feb 15;73(3):394-403
pubmed: 11884936
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):332-345
pubmed: 27940460
J Am Soc Nephrol. 2015 Jun;26(6):1443-8
pubmed: 25573908
Semin Immunopathol. 2014 Jul;36(4):421-9
pubmed: 24402710
Intern Med. 2015;54(17):2213-7
pubmed: 26328649
Case Rep Nephrol. 2019 Oct 9;2019:7304786
pubmed: 31687235
Kidney Int. 2018 Nov;94(5):1013-1022
pubmed: 30348286
J Nephrol. 2010 Nov-Dec;23(6):717-24
pubmed: 20301082
Nat Rev Nephrol. 2019 Dec;15(12):750-765
pubmed: 31654044
Transplantation. 2016 Feb;100(2):284-7
pubmed: 26247557
J Am Soc Nephrol. 2011 Nov;22(11):2129-37
pubmed: 21997394
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
J Am Soc Nephrol. 2013 Apr;24(5):702-11
pubmed: 23431071
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517
pubmed: 28242845
J Am Soc Nephrol. 2012 Nov;23(11):1769-76
pubmed: 22997260
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):911-913
pubmed: 30952629